Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

VS-6063

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

defactinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
OBJECTIVES KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need… 
2018
2018
Effect of FAK inhibitor VS‐6063 (defactinib) on docetaxel efficacy in prostate cancer
Docetaxel, the standard chemotherapy for metastatic castration‐resistant prostate cancer (CRPC) also enhances the survival of… 
Highly Cited
2018
Highly Cited
2018
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
ABSTRACT The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of… 
2017
2017
Inhibition of FAK kinase activity preferentially targets cancer stem cells
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
AbstractPurpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and… 
  • table 1
  • table 2
  • figure 1
  • table 3
Highly Cited
2015
Highly Cited
2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
SummaryObjective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK… 
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2015
2015
Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… 
2014
2014
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.
5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to… 
Highly Cited
2013
Highly Cited
2013
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
BACKGROUND We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE